New drug aims to calm inflammation in kidney dialysis patients

NCT ID NCT07619820

Recruiting now Disease control Sponsor: CSL Behring Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This early-stage trial tests a drug called CSL300 (clazakizumab) in 24 Chinese adults with end-stage kidney disease who are on dialysis. The drug is an antibody that blocks interleukin-6, a protein involved in inflammation. The main goal is to see how the drug moves through the body and whether it is safe, not yet to measure if it improves health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Clazakizumab (CSL300), a lab-made antibody that blocks interleukin-6, given as an injection
What this could lead to: If successful, this could point toward a new way to reduce inflammation in dialysis patients, potentially improving their long-term outcomes.
What could go wrong: This is a very early (Phase 1b), small (24 people) safety and dosing study. It is not designed to prove the drug works, and side effects like infections are a known risk with this type of drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis chronic kidney disease diabetes mellitus end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE KIDNEY DISEASE (ESKD)

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.